196 related articles for article (PubMed ID: 34074731)
1. Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug.
Hussain Z; Zhu J; Ma X
Drug Metab Dispos; 2021 Aug; 49(8):679-682. PubMed ID: 34074731
[TBL] [Abstract][Full Text] [Related]
2. Pyrazinamide induced hepatic injury in rats through inhibiting the PPARα pathway.
Zhang Y; Guo H; Hassan HM; Ding PP; Su Y; Song Y; Wang T; Sun L; Zhang L; Jiang Z
J Appl Toxicol; 2016 Dec; 36(12):1579-1590. PubMed ID: 27071702
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats.
Zhang Y; Jiang Z; Su Y; Chen M; Li F; Liu L; Sun L; Wang Y; Zhang S; Zhang L
J Appl Toxicol; 2013 Aug; 33(8):807-19. PubMed ID: 22431067
[TBL] [Abstract][Full Text] [Related]
4. A novel mechanism underlies the hepatotoxicity of pyrazinamide.
Shih TY; Pai CY; Yang P; Chang WL; Wang NC; Hu OY
Antimicrob Agents Chemother; 2013 Apr; 57(4):1685-90. PubMed ID: 23357778
[TBL] [Abstract][Full Text] [Related]
5. Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish Larvae.
Zhang Y; Liu K; Hassan HM; Guo H; Ding P; Han L; He Q; Chen W; Hsiao CD; Zhang L; Jiang Z
Antimicrob Agents Chemother; 2016 Dec; 60(12):7347-7356. PubMed ID: 27697757
[TBL] [Abstract][Full Text] [Related]
6. Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport.
Guo HL; Hassan HM; Zhang Y; Dong SZ; Ding PP; Wang T; Sun LX; Zhang LY; Jiang ZZ
Toxicol Sci; 2016 Aug; 152(2):417-28. PubMed ID: 27255380
[TBL] [Abstract][Full Text] [Related]
7. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
8. An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage.
Goh ZH; Tee JK; Ho HK
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466226
[TBL] [Abstract][Full Text] [Related]
9. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
10. Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs.
Liu L; Li X; Huang C; Bian Y; Liu X; Cao J; Qu W; Miao L
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):527-537. PubMed ID: 32436768
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
Gopal P; Grüber G; Dartois V; Dick T
Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175
[TBL] [Abstract][Full Text] [Related]
12. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
13. Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid.
Rawat A; Chaturvedi S; Singh AK; Guleria A; Dubey D; Keshari AK; Raj V; Rai A; Prakash A; Kumar U; Kumar D; Saha S
Hum Exp Toxicol; 2018 Apr; 37(4):373-389. PubMed ID: 28425350
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.
Tostmann A; Boeree MJ; Peters WH; Roelofs HM; Aarnoutse RE; van der Ven AJ; Dekhuijzen PN
Int J Antimicrob Agents; 2008 Jun; 31(6):577-80. PubMed ID: 18358703
[TBL] [Abstract][Full Text] [Related]
15. Impact of the host environment on the antitubercular action of pyrazinamide.
Lamont EA; Baughn AD
EBioMedicine; 2019 Nov; 49():374-380. PubMed ID: 31669220
[TBL] [Abstract][Full Text] [Related]
16. PanB over-representation as part of pyrazinamide action: a proteomic insight.
Barros ILE; Meneguello JE; Ghiraldi-Lopes LD; Arita GS; de Oliveira Silva JV; Ferracioli KRC; de Lima Scodro RB; Siqueira VLD; Pilau EJ; Campanerut-Sá PAZ; Cardoso RF
Future Microbiol; 2021 Nov; 16():1303-1308. PubMed ID: 34743541
[No Abstract] [Full Text] [Related]
17. Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity.
Tasduq SA; Kaisar P; Gupta DK; Kapahi BK; Maheshwari HS; Jyotsna S; Johri RK
Phytother Res; 2005 Mar; 19(3):193-7. PubMed ID: 15934014
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide.
Gu P; Constantino L; Zhang Y
J Med Microbiol; 2008 Sep; 57(Pt 9):1129-1134. PubMed ID: 18719183
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy.
Kandula NR; Dworkin MS; Carroll MR; Lauderdale DS
Am J Prev Med; 2004 Feb; 26(2):163-6. PubMed ID: 14751331
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
